¹Edward Tirtananda Wikanta,²Prasetyowati Subchan,³Agung Putra

¹Postgraduate student of the Department of Biomedical Sciences in Medical Sciences, Faculty of Medicine, Universitas Islam Sultan Agung, Jl Kaligawe KM 4 Semarang 50012

²Department of Biomedical Sciences, Faculty of Medicine, Universitas Islam Sultan Agung, Jl Kaligawe KM 4 Semarang 50012

³Department of Anatomical Pathology, Faculty of Medicine, Universitas Islam Sultan Agung, Jl Kaligawe KM 4 Semarang 50012

Psoriasis is caused by chronic inflammation of the skin that occurs in various countries. Current therapy is still dominated by long-term anti-inflammatory which causes various side effects. Hypoxic secretome mesenchymal stem cells (SH-MSCs) contain soluble molecule bioactive anti-inflammatory cytokines that can suppress inflammation. However, the role of SH-MSCs on IL-6 gene expression in psoriasis-like has not been studied until now. The aim of this study was to determine the effect of SH-MSC administration on IL-6 gene expression in Psoriasis-like rats induced by IMQ 100 mg. The research design is an experimental posttest control group design. The experimental subject was divided into four treatment groups consisting of a healthy group (no treatment), positive control group (only IMQ 100 mg), P1 group (SH-MSC therapy 100 μL/kgBW in 100 mg cream) and P2 group (SH-MSCs therapy 200 µL/kgBW in 100 mg cream). P1 and P2 were given SH-MSC topically for 14 days. At the end of the treatment, termination, extraction skin and IL-6 gene expression analysis by qRT-PCR. The results of this study showed that the mean expression of the IL-6 gene in the healthy group was: 1.00±0.00; positive control: 6.16±1.19, P1: 3.06±1.65, P2: 1.06±0.41. Analysis data using Kruskal Wallis test with p< 0.05 and Mann Whitney p < 0.05 so that there was a significant difference between treatment group. The administration of SH-MSC had a significant effect on improving conditions in psoriasis-like model rats as indicated by a decrease in IL-6 gene expression.

IL-6 gene, SH-MSCs, psoriasis

1) Febrina D, Hindritiani R RK. Case Report: Side Effects of Long Term Topical Corticosteroids on the Face. Syifa' Med. 2018;8(2).

2) Aranti R KY. Side Effects on the Oral Cavity Due to Cyclosporin Therapy. Dentofacial. 2013;12(1):49–53.

3) Murniastuti DS DR. Use of Methotrexate in Pediatric Dermatosis. MDVI. 2019;46(1):45–50.

4) Michalek, I. M., Loring, B., & John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol. 2016;31(2):205–12.

5) Susanti R, Adi MS, Susanto HS SS. Description of the Quality of Life of Psoriasis Sufferers in the Psobat Community, Central Java. J Public Health. 2020;8(3).

6) Sutrisman IP, Antari AD, Putra A, Irawan RCS HF. Secretome Hypoxia-Mesenchymal Stem Cells Regulate IL-10 Concentrations in STZ-induced Type 1 Diabetes Rats. Int J Cell Biomed Sci. 2022;1(2):56–64.

7) Agung Putra, Widyatmoko A, Ibrahim S, Amansyah F, Amansyah F, Berlian MA, et al. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. Clin Pract Artic. 2021;

8) Konala VBR, Bhonde R, Pal R. Secretome studies of mesenchymal stromal cells (MSCs) isolated from three tissue sources reveal subtle differences in potency. Vitr Cell Dev Biol Anim. 2020;56(9):689–700.

9) Tarini Nawamalie Abeysinghe Gunawardena, Mohammad Tariqur Rahman, Basri Johan Jeet Abdullah NHAK. Conditioned media derived from mesenchymal stem cell cultures: The next generation for regenerative medicine. . J Tissue Eng Regen Med. 2019;13(4):569–86.

10) Eleuteri S FA. Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications. Int J Mol Sci. 2019;20(18):4597.

11) Bartaula-Brevik S, Bolstad AI, Mustafa K, Pedersen TO. Stem Cell Research & Therapy Secretome of Mesenchymal Stem Cells Grown in Hypoxia Accelerates Wound Healing and Vessel Formation In Vitro ClinMed International Library. Int J Stem Cell Res Ther. 2017;4(1).

12) Badanthadka, Murali, D’Souza, Lidwin and Salwa F. Strain specific response of mice to IMQ-induced psoriasis. J Basic Clin Physiol Pharmacol. 2021;32(5):959–68.

13) Tanaka, T., Narazaki, M., & Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb Perspect Biol. 2014;6(10).

14) Meglio P, Villanova F,Napolitano. L. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol. 2013;1.

15) Saggini, A., Chimenti, S., & Chiricozzi A. IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants. J Immunol Res. 2014;1–10.

VOLUME 06 ISSUE 03 MARCH 2023

There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.